Cel-Sci Corp. shares (NYSE:CVM) rose 7 cents, or 11.3 percent, to 69 cents Monday, as the company reported that in 2014 it enrolled almost 200 patients with advanced primary, untreated head and neck cancer into its global pivotal phase III head and neck cancer trial for its investigational immunotherapy Multikine (leukocyte interleukin).